News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
357,658 Results
Type
Article (17165)
Company Profile (78)
Press Release (340415)
Multimedia
Podcasts (42)
Webinars (5)
Section
Business (99665)
Career Advice (773)
Deals (20179)
Drug Delivery (62)
Drug Development (34868)
Employer Resources (62)
FDA (10652)
Job Trends (8124)
News (168537)
Policy (15156)
Tag
2024 BioCapital Digital (2)
2024 BioForest Digital (1)
2024 BioForest Standard (1)
2024 BioMidwest Digital (1)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (2)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (2)
2024 Biotech Beach Standard (1)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (3)
2024 Pharm Country Standard (1)
2025 Lone Star Bio Digital (1)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (1523)
Accelerated approval (4)
Adcomms (8)
Allergies (51)
Alliances (29682)
ALS (56)
Alzheimer's disease (892)
Antibody-drug conjugate (ADC) (55)
Approvals (10693)
Artificial intelligence (167)
Autoimmune disease (16)
Automation (15)
Bankruptcy (148)
Best Places to Work (7034)
BIOSECURE Act (7)
Biosimilars (50)
Biotechnology (50)
Bladder cancer (44)
Brain cancer (17)
Breast cancer (139)
Cancer (1213)
Cardiovascular disease (82)
Career advice (631)
Career pathing (9)
CAR-T (87)
Cell therapy (240)
Cervical cancer (12)
Clinical research (28198)
Collaboration (483)
Compensation (110)
Complete response letters (5)
COVID-19 (1266)
CRISPR (31)
C-suite (114)
Cystic fibrosis (51)
Data (1219)
Decentralized trials (2)
Denatured (12)
Depression (23)
Diabetes (142)
Diagnostics (4162)
Digital health (13)
Diversity (2)
Diversity, equity & inclusion (16)
Drug discovery (62)
Drug pricing (44)
Drug shortages (10)
Duchenne muscular dystrophy (25)
Earnings (37533)
Editorial (16)
Employer branding (10)
Employer resources (56)
Events (45639)
Executive appointments (364)
FDA (11424)
Featured Employer (17)
Friedreich's ataxia (4)
Frontotemporal dementia (3)
Funding (372)
Gene editing (69)
Generative AI (15)
Gene therapy (160)
GLP-1 (287)
Government (1988)
Grass and pollen (1)
Guidances (40)
Healthcare (11014)
Huntington's disease (10)
IgA nephropathy (18)
Immunology and inflammation (65)
Indications (15)
Infectious disease (1328)
Inflammatory bowel disease (65)
Inflation Reduction Act (7)
Influenza (25)
Intellectual property (43)
Interviews (106)
IPO (8731)
IRA (15)
Job creations (1358)
Job search strategy (545)
Kidney cancer (5)
Labor market (4)
Layoffs (149)
Leadership (7)
Legal (2872)
Liver cancer (41)
Lung cancer (175)
Lymphoma (105)
Machine learning (4)
Management (23)
Manufacturing (190)
MASH (26)
Medical device (10698)
Medtech (10700)
Mergers & acquisitions (11882)
Metabolic disorders (299)
Multiple sclerosis (63)
NASH (7)
Neurodegenerative disease (62)
Neuropsychiatric disorders (14)
Neuroscience (1207)
NextGen: Class of 2025 (3731)
Non-profit (1897)
Northern California (1240)
Now hiring (5)
Obesity (131)
Opinion (116)
Ovarian cancer (35)
Pain (56)
Pancreatic cancer (44)
Parkinson's disease (74)
Partnered (12)
Patents (103)
Patient recruitment (57)
Peanut (35)
People (26482)
Pharmaceutical (20)
Pharmacy benefit managers (12)
Phase I (8853)
Phase II (12013)
Phase III (9753)
Pipeline (636)
Policy (49)
Postmarket research (1123)
Preclinical (3830)
Press Release (62)
Prostate cancer (50)
Psychedelics (8)
Radiopharmaceuticals (115)
Rare diseases (186)
Real estate (3297)
Recruiting (22)
Regulatory (11374)
Reports (20)
Research institute (1432)
Resumes & cover letters (159)
Rett syndrome (3)
RNA editing (1)
RSV (23)
Schizophrenia (36)
Series A (61)
Series B (46)
Service/supplier (10)
Sickle cell disease (21)
Southern California (1095)
Special edition (6)
Spinal muscular atrophy (107)
Sponsored (25)
Startups (1762)
State (2)
Stomach cancer (6)
Supply chain (42)
Tariffs (7)
The Weekly (29)
United States (12063)
Vaccines (301)
Venture capitalists (12)
Weight loss (81)
Women's health (11)
Worklife (5)
Date
Today (72)
Last 7 days (432)
Last 30 days (1315)
Last 365 days (17323)
2025 (5581)
2024 (18854)
2023 (21675)
2022 (30138)
2021 (32727)
2020 (32373)
2019 (26902)
2018 (20088)
2017 (17908)
2016 (16824)
2015 (19298)
2014 (13975)
2013 (11545)
2012 (12947)
2011 (13352)
2010 (11656)
Location
Africa (337)
Alabama (24)
Alaska (4)
Arizona (141)
Arkansas (9)
Asia (19399)
Australia (2662)
California (2936)
Canada (917)
China (247)
Colorado (142)
Connecticut (173)
Delaware (81)
Europe (44397)
Florida (521)
Georgia (98)
Idaho (36)
Illinois (265)
India (19)
Indiana (174)
Iowa (6)
Japan (110)
Kansas (47)
Kentucky (8)
Louisiana (9)
Maine (55)
Maryland (481)
Massachusetts (2164)
Michigan (157)
Minnesota (277)
Mississippi (2)
Missouri (52)
Montana (23)
Nebraska (16)
Nevada (43)
New Hampshire (52)
New Jersey (989)
New Mexico (21)
New York (970)
North Carolina (515)
North Dakota (6)
Northern California (1240)
Ohio (123)
Oklahoma (8)
Oregon (19)
Pennsylvania (635)
Puerto Rico (8)
Rhode Island (19)
South America (502)
South Carolina (13)
South Dakota (1)
Southern California (1095)
Tennessee (44)
Texas (524)
Utah (111)
Virginia (77)
Washington D.C. (21)
Washington State (322)
West Virginia (2)
Wisconsin (32)
357,658 Results for "custom biogenic systems".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
Sage Rejects Biogen’s Unsolicited Offer, Will Seek Strategic Alternatives
Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the embattled biotech at just $469 million.
January 27, 2025
·
1 min read
·
Annalee Armstrong
Earnings
Tariffs Keep Biogen Execs Busy in Q1 but Impacts Expected To Be Minimal
Announcing first-quarter results, Biogen CEO Chris Viehbacher admitted that tariffs are “a new topic for us,” but said he does not expect major impacts—at least for 2025.
May 1, 2025
·
3 min read
·
Annalee Armstrong
Legal
Sage Sues Partner Biogen After Unsolicited Takeover Offer
Biogen’s effort to buy Sage reveals its “desire to expand its pipeline at a discount,” according to analysts from BMO Capital Markets.
January 21, 2025
·
2 min read
·
Tristan Manalac
Neuroscience
Biogen Submits Offer to Buy Embattled Partner Sage
Biogen’s proposed acquisition comes after two difficult years of regulatory and clinical challenges, during which shares of Sage Therapeutics have fallen by more than 90%.
January 13, 2025
·
3 min read
·
Heather McKenzie
Accelerated approval
Inspector General Questions FDA’s Accelerated Approval for Biogen, Sarepta Drugs
An OIG report zeroed in on what it said were three particularly problematic accelerated approvals: Biogen’s Aduhelm, Sarepta’s Exondys and Covis’ Makena.
January 15, 2025
·
2 min read
·
Tristan Manalac
Collaboration
Biogen Taps Royalty Pharma for $250M to Power Phase III Lupus Program
The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the company’s forecasted dip in 2025 revenues.
February 12, 2025
·
2 min read
·
Tristan Manalac
Podcast
RFK Jr. Faces the Senate, Sage Rebuffs Biogen, Obesity Space Expands, More
Donald Trump continues to make waves in biopharma; Sage rejects Biogen’s unsolicited takeover offer; the obesity space sees more action with new company launches, IPOs and fresh data; and experts get ready for an important era in the Duchenne muscular dystrophy space.
January 29, 2025
·
1 min read
·
Heather McKenzie
Business
Dispatches From JPM, Biogen’s Sage Buyout Offer, Pfizer’s Obesity Play, More
J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference. Meanwhile, Biogen proposes to acquire struggling neuro partner Sage, and obesity dominates discussions as Pfizer goes “all in.”
January 15, 2025
·
1 min read
·
Heather McKenzie
Business
Under Pressure to Deal, Biogen Executives Deflect Urgency at JPM25
While investors and analysts push for a deal, Biogen CEO Chris Viehbacher and Head of Development Priya Singhal refuse to make one out of desperation.
January 15, 2025
·
3 min read
·
Annalee Armstrong
Business
5 Reasons Biogen’s Shares Have Dropped 36% in 2024
A slow launch for Alzheimer’s medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a few of the factors that have sent Biogen’s shares down this year.
November 13, 2024
·
7 min read
·
Annalee Armstrong
1 of 35,766
Next
